55 |
Publication
Clin Cancer Res.
2019년
AbstractPurpose: Given that osimertinib is the only approved third-generation EGFR-TKI against EGFR activating and resistant T790M mutated non-small cell lung cancer (NSCLC), additional mutant-selective inhibitors with a higher efficacy, especia…
24.02.20
483
|
|
54 |
Publication
Lung Cancer
2019년
AbstractBackground: With the advance of immunotherapy, treatment of non-small-cell lung cancer (NSCLC) has revolutionized by having anti-PD-1 therapy in front-line setting. In this era of cancer immunotherapy, humanized mouse models which recapitulate hum…
24.02.20
558
|
|
53 |
Publication
Sci Rep
2019년
AbstractAdequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies and novel …
24.02.20
480
|
|
52 |
Publication
Ann Oncol
2019년
AbstractBackground: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However…
24.02.20
461
|
|
51 |
Publication
Journal of Cancer Research and Clinical Oncology
2018년
AbstractPurpose: Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if the…
24.02.20
334
|
|
50 |
Publication
Cancer Research
2018년
AbstractAnaplastic lymphoma kinase (ALK) inhibitors are highly effective in patients with ALK fusion–positive lung cancer, but acquired resistance invariably emerges. Identification of secondary mutations has received considerable attention, but most…
24.02.20
367
|
|
49 |
Publication
Lung Cancer
2018년
AbstractBackground: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) f…
24.02.20
296
|
|
48 |
Publication
J Thorac Oncol
2017년
AbstractBackground: Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. We established a transgenic mouse model that expresses t…
24.02.20
331
|
|
47 |
Publication
Oncotarget
2016년
AbstractProfilin-like protein in Toxoplasma gondii (TgPLP) is a Toll-like receptor (TLR) agonist. In this study, we investigated whether TgPLP has an adjuvant effect on immune function in autologous whole-tumor-cell vaccine (AWV) treatment. Mice vaccinated wit…
24.02.20
339
|
|
46 |
Publication
Oncogenesis
2016년
AbstractAberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibi…
24.02.20
386
|
|
45 |
Publication
Scientific reports
2016년
AbstractTo investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC),…
24.02.20
419
|
|
44 |
Publication
Lung Cancer
2016년
AbstractObjectives: The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutation, and overexpression are frequent in non-small cell lung cancer (NSCLC). We investigated in vitro and in vivo antitumor activity of ER2, a novel…
24.02.20
513
|
|
43 |
Publication
Oncotarget
2015년
AbstractThe purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, wh…
24.02.20
440
|
|
42 |
Publication
Mol Cancer Ther
2015년
AbstractRET rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in RET-rearranged LADC has not been reported. The aims of the study are to explore a…
24.02.20
398
|
|
41 |
Poster
AACR
2023년
24.02.16
459
|
|